Harvard Bioscience, Inc. (HBIO) Financials

HBIO Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 77.9 million 67.9 million
Dec. 31, 2025 80.1 million 66.3 million
Sept. 30, 2025 78.0 million 63.9 million
June 30, 2025 80.1 million 64.4 million

HBIO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -1.1 million 257000
Dec. 31, 2025 -545000 459000
Sept. 30, 2025 623000 324000
June 30, 2025 2.5 million 472000

HBIO Net Income

No data available :(

HBIO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 7.1 million 36.2 million 6.4 million
Dec. 31, 2025 8.6 million 35.9 million 6.9 million
Sept. 30, 2025 6.8 million - 7.3 million
June 30, 2025 7.4 million - 8.5 million

HBIO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 4.5 million
Dec. 31, 2025 4.4 million
Sept. 30, 2025 4.5 million
June 30, 2025 4.4 million

HBIO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 426000 2.3 million 10.0 million 5.3 million
Dec. 31, 2025 449000 2.2 million 9.2 million 5.1 million
Sept. 30, 2025 207000 2.1 million 8.8 million 4.6 million
June 30, 2025 233000 2.2 million 8.8 million 4.5 million

HBIO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 20.8 million 8.5 million
Dec. 31, 2025 23.7 million 9.6 million
Sept. 30, 2025 20.6 million 8.6 million
June 30, 2025 20.5 million 10.1 million

HBIO Revenue by Segment
Graph available only for paid members. Upgrade to see it.

HBIO

Price: $6.20

52 week price:
3.70
9.40

Payout Ratio Range:
-26.46%
-0.80%

Earnings Per Share: -2.15 USD

Exchange: NGM

Sector: Healthcare

Industry: Medical Instruments & Supplies

Country: United States

Volume: 13674

Ebitda: 836000

Market Capitalization: 29.3 million

Links: